Joinpoint regression analysis of the sex-specific ASRs for PUD globally from 1990 to 2021. by Wende Hao (10315597)

Age-specific numbers and rates of PUD globally in 2021 for both sexes. by Wende Hao (10315597)

Proportion of PUD DALYs and deaths attributable to smoking by gender, SDI quintile, and GBD region in 1990 and 2021. by Wende Hao (10315597)

Predicted trends in Age-standardized rates of PUD for both sexes globally over the next 19 years (2022-2040). by Wende Hao (10315597)

Table1_Modified cognitive behavioral therapy approach reduces loudness discomfort levels for an autistic child with hyperacusis: case report.docx by Tana B. Carson (13600824)

“…Introduction<p>Hyperacusis is common among the autistic population, with a lifetime prevalence estimated at up to 60% compared to 17.1% in those without autism. …”

The comparison of the Spectral Exponent in hemispherotomy with a reference pediatric sample across wakefulness and NREM Sleep reveal values compatible with deep sleep in the isolat... by Michele Angelo Colombo (22446342)

A) TAC of SeNPs. by Pompido Chilala (21578182)

Regulation of NF-κB target genes mRNA levels in <i>L</i>. <i>intracellularis</i> infected PK-15 cells. by Huan W. Yang (19746645)

<i>N. parisii</i> induces global changes to <i>C. elegans</i> lipidome. by Hala Tamim El Jarkass (16625309)

Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. by Xueqin lu (22250795)

General procedure for the synthesis of B. by Xueqin lu (22250795)

The Laboratory Animal Flow Diagram. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

¹³C NMR spectra for Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

The structures of T3 and Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

Synthesis process of Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

ESI-HRMS spectra for Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

Effects of Kylo-0603 on body weight, organ weight, and body fat content. by Xueqin lu (22250795)

The trends of cholesterol metabolism-related gene expression in liver tissue. by Xueqin lu (22250795)

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)